Mirador Therapeutics has entered into an exclusive worldwide license agreement with Kira Pharmaceuticals for KP-301, a potentially long-acting, sweeping anti-C5a antibody designed to inhibit C5a/C5aR-mediated inflammation. The agreement expands Mirador’s precision immunology portfolio into inflammatory vascular disease. Kira will receive $12 million upon signing. The C5a/C5aR axis is clinically and commercially validated in ANCA-associated vasculitis […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!